We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
"Smart" Brain Stimulators Could Treat Parkinson's Symptoms
News

"Smart" Brain Stimulators Could Treat Parkinson's Symptoms

"Smart" Brain Stimulators Could Treat Parkinson's Symptoms
News

"Smart" Brain Stimulators Could Treat Parkinson's Symptoms

Nuri Ince, associate professor of biomedical engineering at the University of Houston. Credit: University of Houston
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of ""Smart" Brain Stimulators Could Treat Parkinson's Symptoms"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Researchers at the University of Houston have found neuro biomarkers for Parkinson's disease that can help create the next generation of "smart" deep brain stimulators, able to respond to specific needs of Parkinson's disease patients. Those with the disease often undergo the high-frequency brain stimulation, a well-established therapy for the progressive nervous system disorder that affects movement, but the therapy has been imprecise.


Currently, stimulators can only be programmed clinically and are not adaptable to the fluctuating symptoms of the disease which can include tremors slowness or inability to walk. The biomarkers are key to improving the technology to make it responsive, or smart.


"We can now make the closed-loop stimulator adaptive to sense a patient's symptoms, so it can make the adjustments to the fluctuations in real time, and the patient no longer has to wait for weeks or months until the doctor can adjust the device," said Nuri Ince, associate professor of biomedical engineering. He and doctoral student Musa Ozturk, lead author of the paper, published their findings in Movement Disorders journal.


Nearly 10 million people worldwide are living with Parkinson's disease and approximately 60,000 Americans are diagnosed with the disease each year.


Redefining coupling

The team also reports a new understanding of the electrophysiology of Parkinson's disease after examining cross frequency coupling in the subthalamic nucleus of patients with Parkinson's disease both in the OFF state (before medication) and the ON state (after medication). Coupling, the interaction between the brain waves, has been reported in the past, but its significance and functional role have not been well understood.


The team reports that in the OFF state, the amplitude of high-frequency brain wave oscillations in the 200-300Hz range was coupled with the phase of low-beta (13-22Hz) in all patients. After transition to the ON state, three distinct coupling patterns were observed among subjects. Among these, patients showing ON coupling between high-beta (22-30Hz) and high-frequency oscillations in the 300-400Hz range had significantly greater improvement in bradykinesia, or slowness of movement, one of the cardinal manifestations of Parkinson's disease.


"Previous research showed coupling only existed in the basal ganglia of untreated patients and assumed to block the brain from functioning properly," said Ozturk. "We found that strong coupling also exists in treated patients, though at different frequencies, so in effect we have 'cleared coupling's name' and showed the frequencies involved in coupling impacts whether its effects are negative or positive."

Reference: Ozturk, M., Abosch, A., Francis, D., Wu, J., Jimenez‐Shahed, J., & Ince, N. F. (n.d.). Distinct subthalamic coupling in the ON state describes motor performance in Parkinson’s disease. Movement Disorders, 0(0). https://doi.org/10.1002/mds.27800

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement